Pharmacological effect and clinical evaluation of tarlatamab against small cell lung cancer

doi:10.19803/j.1672-8629.20240354

Abstract

Abstract: Small cell lung cancer (SCLC) is a highly invasive neuroendocrine carcinoma that is prone to metastasis and progression, with high rates of drug resistance and recurrence. The current treatment options have limited benefits for patient survival. On May 16, 2024, the FDA approved the marketing of tarlatamab, providing a new treatment plan for SCLC patients who have previously received first-line or second-line treatment. Clinical studies have shown that this drug is effctive and safe. This article reviews the pharmacological effects，clinical studies，safety，usage and dosage of tarlatamab.

Key words: small cell lung cancer, tarlatamab, clinical evaluation, safety

CLC Number:

R979.1

ZHENG Li, ZHANG Kaihua, SUN Xuelin. Pharmacological effect and clinical evaluation of tarlatamab against small cell lung cancer[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1078-1080.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240354

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I9/1078

References

[1] CHEN G, LI Y, JIANG CH, et al.Analysis of one case of deep coma and severe drug-induced liver injury caused by sofantinib tablets and sustained-release hydroxycodone tablets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(11): 1296-1298, 1302.
[2] RUDIN CM, BRAMBILLA E, FAIVRE FC, et al.Small-cell lung cancer[J]. Nature Reviews Disease Primers, 2021, 7(1): 3.
[3] HORN L, MANSFIELD AS, SZCZESNA A, et al.First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. The New England Journal of Medicine, 2018, 379(23): 2220-2229.
[4] PAZ-ARES L, CHEN Y, REINMUTH N, et al.Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN[J]. ESMO Open, 2022, 7(2): 100408.
[5] DOMINE M, MORAN T, ISLA D, et al.SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)[J]. Clinical & Translational Oncology, 2020, 22(2): 245-255.
[6] SALTOS A, ANTONIA S.Breaking the impasse: advances in treatment of small cell lung cancer[J]. Clinics in Chest Medicine, 2020, 41(2): 269-280.
[7] GANTI AKP, LOO BW, BASSETTI M, et al.Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. Journal of the National Comprehensive Cancer Network, 2021, 19(12): 1441-1464.
[8] TENDLER S, RUDIN CM.Tarlatamab: new star on the horizon for small-cell lung cancer?[J] Journal of Clinical Oncology, 2023, 41(16): 2877-2880.
[9] SAUNDERS LR, BANKOVICH AJ, ANDERSON WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo[J]. Science Translational Medicine, 2015, 7(302): 302ra136.
[10] SABARI JK, LOK BH, LAIRD JH, et al.Unravelling the biology of SCLC: implications for therapy[J]. Nature Reviews Clinical Oncology, 2017, 14(9): 549-561.
[11] FDA. Tarlatamab-dlle (Imdelltra)[EB/OL]. (2024-05-16)[2024-05-26]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf.
[12] AHN MJ, CHO BC, FELIP E, et al.Tarlatamab for patients with previously treated small-cell lung cancer[J]. The New England Journal of Medicine, 2023, 389(22): 2063-2075.
[13] CHUNG HC, PIHA-PAUL SA, LOPEZ-MARTIN J, et al.Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies[J]. Journal of Thoracic Oncology, 2020, 15(4): 618-627.
[14] READY N, FARAGO AF, DE BF, et al.Third-line nivolumab monotherapy in recurrent SCLC: checkmate 032[J]. Journal of Thoracic Oncology, 2019, 14(2): 237-244.
[15] PAZ-ARES L, CHAMPIAT S, LAI WV, et al.Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study[J]. Journal of Clinical Oncology, 2023, 41(16): 2893-2903.
[16] PAZ-ARES L, DVORKIN M, CHEN Y, et al.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212): 1929-1939.
[17] TRIGO J, SUBBIAH V, BESSE B, et al.Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial[J]. The Lancet Oncology, 2020, 21(5): 645-654.
[18] VON PAWEL J, JOTTE R, SPIGEL DR, et al.Randomized phase Ⅲ trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer[J]. Journal of Clinical Oncology, 2014, 32(35): 4012-4019.